Craig Hilts

CRAIG HILTS represents domestic and international companies in a wide range of capital markets, securities, public company reporting, and disclosure and corporate governance matters, with a particular emphasis on the life sciences and technology industries. Craig also frequently represents investment banks in capital markets transactions in the life sciences and technology sectors.

He has successfully represented clients in a wide range of complex capital markets transactions, including numerous initial public offerings, follow-on equity offerings, PIPEs, at-the-market offerings, senior debt offerings, convertible debt offerings, and liability management transactions.

Craig serves as principal outside counsel for many life sciences companies in which he provides strategic advice to boards of directors and management teams regarding significant transactions and public company obligations. Craig was named a 2021 “Top Rising Star” by The Deal.

• Nuvalent in its US$500 million public offering.
• Constellation Pharmaceuticals in its US$60 million initial public offering, US$450 million in multiple follow-on public offerings, and US$65 million private placement.
• Cue Health in its US$230 million initial public offering.
• Fulcrum Therapeutics in its US$125 million initial public offering, US$150 million follow-on public offering, and US$68.5 million private placement.
• Karyopharm Therapeutics in its US$165 million private placement.
• Karyopharm Therapeutics in its US$150 million private placement of convertible notes.
• Karyopharm Therapeutics in its strategic refinancing transactions.
• Pandion Therapeutics in its US$135 million initial public offering.
• Translate Bio in its US$121.6 million initial public offering.
• Verve Therapeutics in its US$306 million initial public offering and multiple follow-on public offerings.
• Underwriters in the US$175 million public offering by Immuneering Corporation.
• Underwriters in the US$655 million initial public offering of Dynatrace and multiple follow-on public offerings by stockholders of Dynatrace.
• Underwriters in the US$90 million initial public offering of Graybug Vision.
• Underwriters in the US$143.8 million initial public offering of Ikena Oncology.
• Underwriters in the US$172.5 million initial public offering of Rhythm Pharmaceuticals.
• Placement agents in the US$280 million private placement by Cullinan Therapeutics.
• Analog Devices in its US$1.1 billion senior notes offering.
• Casella Waste Systems in multiple follow-on public offerings of common stock.
• Medtronic in multiple public offerings of senior notes.
• MKS Instruments in its US$1.4 billion convertible notes offering.
• S&P Global in its $US750 million Rule 144A offering of senor notes.

Some of the above matters were handled prior to joining Sidley.

• Board of Advisors, Life Science Cares
• Business Transactions Section, Boston Bar Association, 2018–2020